J Dig Cancer Res.  2019 Jun;7(1):1-4. 10.0000/jdcr.2019.7.1.1.

Chemotherapy for Patients with Colorectal Cancer - When and How?

Affiliations
  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. kjh8517@daum.net

Abstract

It is important to choose the appropriate treatment option for patients with colorectal cancer (CRC), because it could affect the prognosis of patients. Chemotherapy is effective in prolonging survival and time to progression in patients with advanced CRC. Adjuvant chemotherapy have been reported to reduce the recurrence rate of colorectal cancer by 30% in patients with stage 3 or high risk of stage 2 CRC. Although palliative chemotherapy does not offer long-term benefits, as life expectancy remains below 12 months in most of those receiving treatment, recent developments in the treatment including target agents and immunotherapy have improved the median overall survival time in patients with metastatic CRC by up to 30 months. Chemotherapy for patients with CRC is classified into neoadjuvant, adjuvant, and palliative therapy according to the status of patients. In this review, I summarized the chemotherapy for patients with CRC, which applying in clinical practice.

Keyword

Colorectal neoplasm; Chemotherapy

MeSH Terms

Chemotherapy, Adjuvant
Colorectal Neoplasms*
Drug Therapy*
Humans
Immunotherapy
Life Expectancy
Palliative Care
Prognosis
Recurrence
Full Text Links
  • JDCR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr